DeutschNewstral
Article
bizjournals.com on 2018-06-25 13:00
Cambridge biotech startup grabs $65M to tackle liver disease
Related news
- Cambridge biotech with rare blood disease drug secures $59Mbizjournals.com
- Cambridge rare disease biotech Synageva to be acquired for $8.4Bbizjournals.com
- Cambridge RNA startup raises $45M to break into CNS, liver diseasebizjournals.com
- Merck takes stake in small Cambridge rare disease biotech, lifting sharesbizjournals.com
- Cambridge biotech delivers coronavirus vaccinebizjournals.com
- Biotech startup expands from Cambridge to Watertownbizjournals.com
- Cambridge biotech to return its PPP loanbizjournals.com
- Cambridge biotech relocates to West Coastbizjournals.com
- Cambridge biotech plans manufacturing hub in Marylandbizjournals.com
- Cambridge biotech Werewolf gets $72M funding roundbizjournals.com
Cambridge footwear firm grabs another retail awardcambridgeindependent.co.uk- FUK biotech signs $1bn deal to develop liver disease drugsft.com
Regeneron partners with Alnylam to pursue liver disease treatmentwestfaironline.com- Former Cambridge biotech employee imprisoned for insider tradingbizjournals.com
- CRISPR pioneer Feng Zhang's lab spawns a new Cambridge biotechbizjournals.com
- Rockville biotech buys Cambridge gene therapy firm for $86Mbizjournals.com
- Cambridge biotech VC firm Clarus acquired by Blackstonebizjournals.com
- How this Cambridge biotech is changing the drug development gamebizjournals.com
- Cambridge biotech aims to stop neuron death in ALS, Alzheimer'sbizjournals.com
- Like biotech and tech companies, rich millennials flock to Cambridgebizjournals.com